Article Versions Notes

Eiken AP, Schmitz E, Drengler EM, Smith AL, Skupa SA, Mohan K, Rana S, Singh S, Mallareddy JR, Mathew G, et al. The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax. Hemato. 2024; 5(3):321-339. https://doi.org/10.3390/hemato5030024

Eiken, Alexandria P., Elizabeth Schmitz, Erin M. Drengler, Audrey L. Smith, Sydney A. Skupa, Kabhilan Mohan, Sandeep Rana, Sarbjit Singh, Jayapal Reddy Mallareddy, Grinu Mathew, and et al. 2024. "The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax" Hemato 5, no. 3: 321-339. https://doi.org/10.3390/hemato5030024

Eiken, A. P., Schmitz, E., Drengler, E. M., Smith, A. L., Skupa, S. A., Mohan, K., Rana, S., Singh, S., Mallareddy, J. R., Mathew, G., Natarajan, A., & El-Gamal, D. (2024). The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax. Hemato, 5(3), 321-339. https://doi.org/10.3390/hemato5030024